Basilea reports strong revenue growth and significant pipeline progress

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the year 2018.

• Total revenue increased 31% to CHF 133 million
• Revenue from Cresemba® and Zevtera® increased 56% to CHF 82 million
• Positive derazantinib phase 2 interim results and collaboration with Roche on combination with Tecentriq®
• Year-end cash position of CHF 223 million

David Veitch, Chief Executive Officer, said: "We continue to make great progress establishing Zevtera and in particular Cresemba, as global brands. We are very pleased with the strong sales performance in 2018. We have also significantly strengthened our pre-clinical and clinical oncology pipeline through in-licensing transactions. The encouraging interim derazantinib results in the registrational phase 2 study and the recently announced collaboration with Roche support the significant potential value in intrahepatic cholangiocarcinoma and urothelial cancer."

Read the full media release